Comparative Pharmacology
Head-to-head clinical analysis: BRONKOMETER versus DILOR 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOMETER versus DILOR 400.
BRONKOMETER vs DILOR-400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal (70% unchanged), hepatic metabolism (30%)
Category C
Category C
Bronchodilator
Bronchodilator